Two targets, one drug for new EGFR inhibitors.
McNeil
Caroline
C
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D066246:ErbB Receptors / Q000187:drug effects*; D006801:Humans; D000077341:Lapatinib; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000187:drug effects*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000187:drug effects
D000970:Antineoplastic Agents; D066246:ErbB Receptors; D000077341:Lapatinib; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor; C452423:vandetanib